Hospital Vithas Parque San Antonio
- Address
- lock Available on a paid plan
Oncology
At Hospital Vithas Parque San Antonio in Malaga, the clinical trial portfolio is focused on oncology, with research centered on neoplasms and a strong emphasis on breast cancer. The studies are designed to help improve treatment options for people with early-stage disease and to reduce the risk of recurrence.
- Breast neoplasms and ER+/HER2- early breast cancer
- Evaluation of new endocrine therapy approaches for preventing recurrence
- Comparison of emerging treatments with standard care to improve long-term outcomes
These trials aim to test whether newer hormone-based therapies can offer better protection than current treatment strategies, supporting more effective follow-up care for patients with hormone receptor-positive breast cancer.
Breast Cancer Recurrence Prevention
Research at this site includes studies in breast cancer that focus on keeping the disease from returning after initial treatment. The main goal is to evaluate whether newer therapies can improve the effectiveness of post-treatment care for patients at higher risk of recurrence.
- Prevention of recurrence in ER+/HER2- breast cancer
- Testing novel adjuvant endocrine therapy strategies
- Assessing treatment benefit against standard therapy options
This work reflects a broader effort in oncology to refine long-term treatment plans and provide more personalized disease control after early breast cancer therapy.
Endocrine-Based Cancer Treatment
The trial activity at Hospital Vithas Parque San Antonio also explores endocrine-based therapy for early breast cancer, with a focus on improving how well treatment prevents disease return in patients with hormone receptor-positive tumors.
- Studying adjuvant treatment options for early-stage breast cancer
- Comparing investigational therapies with standard endocrine therapy
- Supporting better decisions in breast oncology
Overall, the site contributes to research that seeks to make breast cancer care more effective by evaluating whether newer medicines can outperform established approaches in everyday clinical practice.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 4 therapeutic areas and 15 of 25 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1Longboard Pharmaceuticals Inc.2active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Longboard Pharmaceuticals Inc.3trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital Vithas Parque San Antonio
lock Showing 1 of 15 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PRAGMATYK) | Bristol-Myers Squibb Services Unlimited Company | Phase I | Recruiting | May 2026 | — |
IMP list
lock Showing 1 of 25 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins | 2 | Unknown | 2025-10-06 | 2025-10-06 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.